Yan Dong, Dai Hong
Department of Oncology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.
Zhonghua Zhong Liu Za Zhi. 2009 Mar;31(3):217-9.
The aim of this study is to investigate the efficiency and toxicity of the FOLFOX regimen, the combination of oxaliplatin (L-OHP), 5-fluorouracil (5-Fu) and calcium folinate (CF), for patients with locally advanced or metastatic gastric cancer.
Ninety-six patients with locally advanced or metastatic gastric adenocarcinoma, including 72 males and 24 females, were treated with FOLFOX regimen: L-OHP 85 mg/m(2) iv in 2 hours on D1, CF 200 mg/m(2) iv in 2 hours on D1 and D2, 5-Fu 400 mg/m(2) iv on D1 and D2, and then continuous infusion of it at a dose of 600 mg/m(2) for 44 hours. This regimen was repeated every 2 weeks. The first evaluation was done after four cycles. The median cycle of the chemotherapy was 6 (range: 1 to 12 cycles).
Of the 96 patients with gastric cancers, 21 underwent R0 resection and afterward received adjuvant FOLFOX chemotherapy. Ten of those were still alive, while the other 11 died of the disease, with a median disease free survival time of 24.0 months and 3-year survival rate of 51.8%. The other 75 received only palliative chemotherapy due to non-operable advanced disease. Thirty of those achieved partial response (PR), the other 20 had a stable disease (SD), but the remaining 25 experienced disease progression (PD), with an overall response rate of 40.0%. The median TTP and overall survival in those 75 patients was 5.9 and 12.0 months, respectively. All 96 patients were evaluable for toxicity according to NCI criteria. The patients of grade 3 vomiting and neural toxicity were 6 and 4, respectively.
In terms of efficacy and safety, the FOLFOX regimen is effective and well tolerable for patients with locally advanced or metastatic gastric cancers either as adjuvant or palliative chemotherapy.
本研究旨在探讨奥沙利铂（L-OHP）、5-氟尿嘧啶（5-Fu）和亚叶酸钙（CF）联合的FOLFOX方案对局部晚期或转移性胃癌患者的疗效及毒性。
96例局部晚期或转移性胃腺癌患者，其中男性72例，女性24例，接受FOLFOX方案治疗：第1天静脉滴注L-OHP 85 mg/m²，持续2小时；第1天和第2天静脉滴注CF 200 mg/m²，持续2小时；第1天和第2天静脉滴注5-Fu 400 mg/m²，然后以600 mg/m²的剂量持续静脉滴注44小时。每2周重复该方案。4个周期后进行首次评估。化疗的中位周期数为6（范围：1至12个周期）。
96例胃癌患者中，21例接受了R0切除，随后接受辅助FOLFOX化疗。其中10例仍存活，另外11例死于疾病，无病生存期的中位数为24.0个月，3年生存率为51.8%。另外75例因疾病晚期无法手术仅接受姑息化疗。其中30例达到部分缓解（PR），另外20例病情稳定（SD），但其余25例病情进展（PD），总缓解率为40.0%。这75例患者的中位疾病进展时间（TTP）和总生存期分别为5.9个月和12.0个月。所有96例患者均根据美国国立癌症研究所（NCI）标准评估毒性。3级呕吐和神经毒性的患者分别为6例和4例。
就疗效和安全性而言，FOLFOX方案作为辅助或姑息化疗对局部晚期或转移性胃癌患者有效且耐受性良好。
